Susquehanna Fundamental Investments LLC Purchases New Holdings in Immunome, Inc. $IMNM

Susquehanna Fundamental Investments LLC bought a new stake in Immunome, Inc. (NASDAQ:IMNM) in the second quarter, Holdings Channel reports. The institutional investor bought 26,035 shares of the company’s stock, valued at approximately $552,000.

A number of other large investors have also modified their holdings of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Immunome by 0.9% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 188,636 shares of the company’s stock valued at $3,997,000 after buying an additional 1,625 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of Immunome by 10.1% during the 2nd quarter. Wellington Management Group LLP now owns 5,210,216 shares of the company’s stock valued at $110,404,000 after acquiring an additional 478,239 shares in the last quarter. Capstone Investment Advisors LLC acquired a new stake in shares of Immunome during the 2nd quarter valued at about $299,000. Corient Private Wealth LP acquired a new stake in shares of Immunome during the 2nd quarter valued at about $916,000. Finally, Bank of America Corp DE bought a new stake in Immunome in the second quarter valued at about $13,729,000. 44.58% of the stock is currently owned by institutional investors and hedge funds.

Immunome Stock Performance

Shares of NASDAQ:IMNM opened at $27.33 on Thursday. Immunome, Inc. has a twelve month low of $8.66 and a twelve month high of $30.06. The firm has a market cap of $3.10 billion, a PE ratio of -10.80 and a beta of 2.13. The business has a fifty day moving average of $24.67 and a 200-day moving average of $22.51.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.14). On average, analysts anticipate that Immunome, Inc. will post -2.38 EPS for the current fiscal year.

Insider Activity at Immunome

In other news, Director Isaac Barchas sold 101,050 shares of the stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $21.12, for a total transaction of $2,134,176.00. Following the sale, the director directly owned 308,504 shares of the company’s stock, valued at $6,515,604.48. This represents a 24.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Max Rosett sold 60,000 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $18.23, for a total transaction of $1,093,800.00. Following the completion of the sale, the chief financial officer directly owned 54,037 shares of the company’s stock, valued at approximately $985,094.51. This represents a 52.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 682,310 shares of company stock valued at $15,675,566 over the last ninety days. Company insiders own 7.21% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on IMNM shares. Wall Street Zen cut shares of Immunome from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. Citigroup reissued a “buy” rating on shares of Immunome in a report on Thursday, July 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immunome in a report on Friday, July 17th. Wedbush raised their target price on Immunome from $31.00 to $35.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 12th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Immunome in a research note on Thursday, July 9th. Twelve equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $34.64.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.